製品
Agreement broadens access to single cell research in the region
SEATTLE — June 25, 2024 — Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced an agreement with Bogotá, Colombia-based Gencell Pharma to extend Parse’s reach in Colombia specifically and also across South America.
“Demand for Parse’s Evercode single cell sequencing solutions continues to grow in South America as the academic, biotech, and pharma communities discover their scalability and simplicity,” noted Parse Biosciences CEO and co-founder Alex Rosenberg, Ph.D. “Through this partnership with Gencell, we are empowering them to easily adopt the leading single cell sequencing technology.”
The company’s agreement with Gencell Pharma will give South American researchers full access to Parse’s single cell portfolio, including Evercode™ Whole Transcriptome, Evercode TCR, Evercode BCR, Evercode Cell Fixation, Evercode Nuclei Fixation, Gene Capture, CRISPR Detect, and the Parse Biosciences data analysis solution, Trailmaker. The agreement is a continuation of Parse’s ongoing introduction of its products in key international markets, which are also currently available in North America, Europe, Australia, South Korea, Singapore, India, Israel, and New Zealand.
Noted Gencell Pharma CEO Fabio Andres Zapata Gomez, “This partnership with Parse will bring single cell sequencing to a wide range of researchers in South America, all of whom will greatly benefit from its Evercode technology. We’re excited to see what breakthroughs the scientific community in South America is able to achieve with these newly available tools.
About Gencell Pharma
Gencell Pharma is a Colombian company with presence in five countries in the LATAM region and more than 14 years of experience. It is the first regional laboratory to have a Genomic Sequencing Center, and its mission is focused on offering comprehensive health solutions and services in the areas of diagnosis, precision medicine, research, specialized technologies in molecular biology, telemedicine and bioinformatics. For more information, please visit https://gencellpharma.com/ or connect on Facebook, Instagram or LinkedIn.
パース・バイオサイエンシズについて
パース・バイオサイエンシズは、人々の健康と科学研究の進歩を加速することを使命とする、世界的なライフサイエンス企業です。研究者が前例のない規模と容易さでシングルセル・シーケンシングを行えるようにする同社の先駆的アプローチは、がん治療、組織修復、幹細胞治療、腎臓および肝臓疾患、脳の発達、免疫分野における画期的な発見を可能にしています。
Founded based on a transformative technology invented at the University of Washington, Parse has raised over $100 million and is used in nearly 2,000 labs across the world. Its growing portfolio of products includes Evercode Whole Transcriptome, Evercode TCR, Evercode BCR, CRISPR Detect, Gene Capture, and a software tool for data analysis, Trailmaker.
ワシントン州シアトルの活気あるサウス レイク ユニオン地区に本社を置くパース・バイオサイエンシズは、最近3万4000平方フィートの本社と最先端の研究所を
開設しました。本記者発表文の公式バージョンはオリジナル言語版です。翻訳言語版は、読者の便宜を図る目的で提供されたものであり、法的効力を持ちません。翻訳言語版を資料としてご利用になる際には、法的効力を有する唯一のバージョンであるオリジナル言語版と照らし合わせて頂くようお願い致します。
Contact: